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INTRODUCTION
ALZHEIMER’S DISEASE (AD) is the most common form ofage-related dementia (59). It is a complex disorder,
with many molecular triggers synergistically culminating in a
final common pathway. Examination of the atrophied AD
brain reveals a vast range of pathological changes including
widespread neuronal loss, particularly in the hippocampus
and frontal lobes (59). Histopathologically, the AD brain is
characterized by extracellular senile plaques, intracellular
neurofibrillary tangles, and congophilic amyloid angiopathy
(59). Senile plaques are comprised mostly of aggregated de-
posits of a 39–42 amino acid peptide termed beta amyloid
(A), and are often surrounded by activated microglia and
degenerating neurons (reviewed in Ref. 126). A is also
found in deposits within and around blood vessels, and these
deposits comprise the congophilic amyloid angiopathy (59).
Neurofibrillary tangles are abnormal intracellular deposits of
hyperphosphorylated and polymerized forms of the cy-
toskeletal protein tau. The AD brain is under oxidative stress
and A is thought to play a major role in promoting oxidative
damage (24, 76, 79). This review will describe the role of re-
productive hormones in the modulation of A levels and ox-
idative stress in AD.
OXIDATIVE STRESS IN AD
Oxidative stress is recognized as a major neuropathologi-
cal feature of AD, and recent evidence indicates that it may
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ABSTRACT
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by gradual cognitive decline, impair-
ments in speech and language, and dysfunction in the sensorimotor systems, culminating in complete reliance
on nursing care. Oxidative stress, caused by an imbalance in the pro-oxidant/antioxidant mechanisms in the
body, has been implicated in AD pathogenesis, as in many other age-associated diseases such as atherosclero-
sis, Parkinson disease, and amyotrophic lateral sclerosis. Although the hormones estrogen, progesterone, tes-
tosterone, and luteinizing hormone are best known for their roles in reproduction, many studies show these
hormones have other roles, including neuroprotection. Changes in the levels of these hormones that occur in
reproductive senescence are hypothesized to increase risk of AD, as a result of reduced protection against ox-
idative insults. The A peptide, overproduction of which is thought to be a key pathogenic event in the devel-
opment of AD, is neurotoxic, most likely due to its ability to promote oxidative stress. The reproductive hor-
mones are known to influence A metabolism, and this review discusses the beneficial and detrimental effects
these hormones have on A production and oxidative stress, and their relevance in potential AD therapies. An-
tioxid. Redox Signal. 8, 2047–2059.
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indeed be one of the earliest pathological events in the dis-
ease process (89). For example, elevated levels of oxidative
stress markers have been reported in subjects with mild cog-
nitive impairment, who exhibit a high conversion rate to AD
(61, 98). Oxidative stress has also been linked to several other
age-associated conditions such as atherosclerosis, certain
cancers, Parkinson’s disease, and familial amyotrophic lateral
sclerosis. The first report that oxidative stress plays a role in
AD was the discovery of elevated glucose-6-phosphate dehy-
drogenase activity in AD brains (76); this enzyme is known to
help defend against oxidative stress. Since this initial discov-
ery, evidence of elevated levels of lipid peroxidation, as well
as protein and DNA oxidation, have been reported in AD
brains by several laboratories (reviewed in Ref. 97). Studies
of transgenic animal models of AD support the concept that
oxidative stress in AD, as increased levels of oxidative stress
markers have been found in these animals, coinciding with
amyloid deposits (113). The challenge now lies in character-
izing the molecular mechanism(s) that drive these oxidative
changes in AD and finding therapeutic strategies to prevent
and overcome these changes.
REPRODUCTIVE HORMONES 
MODULATE OXIDATIVE STRESS
Inherent gender differences in responses to oxidative
stressors suggest that reproductive hormones have the poten-
tial to modulate the pro-oxidant/antioxidant balance, and
thereby modulate the susceptibility to oxidative stress.
Women have been found to have lower lipid peroxide levels
than men of the same age (77) and animal studies have indi-
cated that the female brain is more resistant to oxidative in-
sults mediated by ischemic injury (48). These gender differ-
ences in oxidative stress susceptibility have been attributed to
reproductive hormones. Comparisons between pre- and post-
menopausal women have detected age-independent increases
in levels of lipid peroxidation markers coupled with de-
creases in levels of antioxidants such as glutathione peroxi-
dase, ascorbic acid, and -tocopherol (77, 110, 129). Simi-
larly, elevated lipid peroxide levels have been reported in
women who have undergone surgically induced menopause
via ovariectomy, corroborating the hypothesized role of the
reproductive hormones in oxidative stress (132).
GENDER DIFFERENCES IN AD
Gender differences have also been reported in the inci-
dence, clinical presentation, and pathology of AD. Whilst
gender differences in AD prevalence are difficult to interpret
due to gender differences in life expectancy, incidence studies
indicate that women are at greater risk of AD, particularly in
the older population (5, 100), and slightly more severe cogni-
tive deficits have been reported in women compared to men
(54). Gender differences in levels of antioxidants and oxida-
tive stress indicators have also been reported in AD. Levels of
the antioxidant enzymes superoxide dismutase and glu-
tathione peroxidase are elevated in AD brains when compared
to controls, and additionally, when compared to their male
counterparts, female AD subjects have significantly greater
levels of these enzymes than male AD subjects (105). The el-
evated antioxidant levels observed in the female AD brains
were hypothesized to reflect a compensatory mechanism off-
setting elevated pro-oxidant species (105). These gender dif-
ferences in AD presentation and pathology may therefore re-
flect gender differences in vulnerability to oxidative insult,
perhaps mediated by gender differences in the levels of the
reproductive hormones following menopause compared to
andropause (male reproductive senescence).
HORMONE REGULATION AND
REPRODUCTIVE SENESCENCE
Steroidal sex hormones are predominantly synthesized in
the gonads under the regulatory control of the gonadotropin
hormones. Relatively small quantities of steroidal sex hor-
mones are also produced in the adrenal glands, placenta,
heart, bone, adipose tissue, and brain (reviewed in Ref. 94).
The gonadotropins, luteinizing hormone (LH) and follicle
stimulating hormone (FSH), are synthesized in and secreted
from the pituitary, and act on the ovary and testes to stimulate
gonadal sex hormone production (Fig. 1). Following repro-
ductive senescence (menopause), the gonads fail to synthe-
size and secrete steroidal sex hormones. Compensatory in-
creases in nongonadal synthesis of steroidal sex hormones
have been recorded (85), nevertheless estrogen, progesterone,
and testosterone deficiencies occur following reproductive
senescence (26). Gonadotropin production and secretion also
increase markedly following reproductive senescence, in a
compensatory measure to stimulate sex hormone production;
however, this is inevitably unsuccessful (26, 78, 88, 122).
REPRODUCTIVE HORMONES AND AD
A large body of evidence indicates that estrogen, proges-
terone, and testosterone are neuroprotective, mediated at least
in part by antiamyloidogenic, antioxidative, and anti-inflam-
matory mechanisms. Consistent with the neuroprotective ef-
fect of the steroidal sex hormones, an association between
AD and depleted levels of estrogen in women, and testoster-
one in men, has been reported (55, 75, 91). Consequently, it
has been hypothesized that depleted sex hormone levels con-
fer neurodegenerative susceptibility to AD. It has also been
speculated that the increased prevalence of AD in women is
the result of depleted estrogen levels following reproductive
senescence (reviewed in Ref. 73). Although superficially this
may seem paradoxical since men also experience testosterone
depletion following reproductive senescence, the loss of go-
nadal function and resulting sex hormone depletion generally
occurs abruptly in women, whereas men experience a gradual
depletion of testosterone over several decades (43, 78, 88,
122). Testosterone depletion in males is also highly variable
between individuals. Sex hormone depletion may also play an
important role in the development of other neurodegenerative
diseases that display similar gender predilections including
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amyotrophic lateral sclerosis, Parkinson disease, multiple
sclerosis, and AIDS-induced dementia (29).
Hormone replacement therapy (HRT) has been examined
as a potential preventative and therapeutic strategy in the
treatment of AD. Initial clinical trials of testosterone replace-
ment therapy in older men have reported selective improve-
ments in cognitive function (8, 57, 111), whilst testosterone
treatment was found to improve the ability to perform daily
tasks and reduce frailty in men with multi-infarct dementia
(8). Another study has also reported that testosterone im-
proves cognitive function in a small cohort of subjects with
AD (117). Surprisingly, clinical trials have found HRT to be
of no benefit to female AD patients (87, 130). Even the po-
tential preventative benefits of HRT are contentious. Whilst
many small studies have reported improved cognition and re-
duced prevalence of AD amongst HRT users (9, 60, 118), the
recent Women’s Health Initiative clinical trial reported HRT
to be detrimental to cognitive function and increase AD risk
(32, 109). It has been argued that the long postmenopausal
delay prior to HRT initiation in the Women’s Health Initiative
study, with all participants 65 years and older, may explain
the detrimental effects observed (73). In light of this, another
HRT clinical trial (Kronos Early Estrogen Prevention Study)
has been initiated in perimenopausal women to re-address the
potential cardioprotective effects of HRT when administered
without a long postmenopausal delay (maximum 36 months
following final menses) (50). Other factors have also been
identified for consideration in interpretation of the WHI
study including the source of hormone (equine estrogens as
compared to synthetic human forms of these hormones) and
mode of delivery (cyclic vs. continuous) (73).
The neuroprotective properties of progesterone have been
most widely studied for the treatment of spinal chord and
traumatic brain injury. Although animal studies indicate that
natural progesterone is neuroprotective, the synthetic proges-
terone, medroxyprogesterone acetate (MPA), is not neuropro-
tective and has been shown to antagonize the neuroprotective
effects of estrogen (112). This is particularly interesting since
MPA was used in the WHI clinical trials; therefore, it is clear
there are a number of issues to be addressed before a defini-
tive conclusion regarding the preventative benefit of HRT
against AD can be determined.
More recently, elevated postmenopausal and andropausal
LH have also been identified as potential neurodegenerative
factors in AD. Supporting this notion, significantly elevated
serum LH levels have been reported in dementia and AD sub-
jects (19, 108). Elevated LH levels have also been confirmed
immunohistochemically in the hippocampus of AD brains
when compared to control brains, and the hippocampus is a
brain region particularly vulnerable to degeneration in AD
(18). Accordingly, it has been hypothesized that elevated LH
confers susceptibility to neurodegeneration in AD (19).
Sex hormone regulation and LH homeostasis are inextrica-
bly linked. These hormones also play a role in the modulation
of A peptide production (overproduction of which is
thought to be a key event in AD pathogenesis) and inflamma-
tory processes, both of which may result in the generation of
oxidative stress.
AMYLOID PRECURSOR PROTEIN (APP)
AND A METABOLISM IN AD
Causative genetic mutations have been identified that ac-
count for <5% of AD cases (127). These include mutations in
the parent molecule of A, the amyloid precursor protein
(APP), and mutations in genes coding for the presenilin pro-
teins that are involved in the proteolytic processing of APP
(67). These mutations lead to the increased production of A,
particularly the longer, more amyloidogenic form A1–42
(67). In AD, A peptides aggregate into insoluble fibrils, and
over time these deposit in the brain to produce the character-
istic amyloid plaques. These studies, as well as many in vitro
and transgenic mice studies, have led to the “amyloid hypoth-
esis,” which states that A accumulation is central to AD
Hypothalamus
GnRH
GnRH receptors
Pituitary
Negative
Feedback
Negative FeedbackLH & FSH
LHR & FSHR
Gonads
Testosterone
Estrogen
Progesterone
FIG. 1. Reproductive hormone homeostasis: the hypothala-
mic pituitary axis. Gonadotropin releasing hormone
(GnRH) secreted from the hypothalamus binds with GnRH re-
ceptors on the pituitary activating production and secretion of
LH and FSH. LH and FSH interact with their respective recep-
tors (LHR and FSHR) on the gonads to stimulate gonadal sex
hormone production (estrogen and progesterone from the
ovaries, testosterone from the testes). The gonadal sex hor-
mones exert negative feedback on the hypothalamus and pitu-
itary to inhibit further GnRH and gonadotropin secretion. LH
and FSH also exert negative feedback on the pituitary to inhibit
further gonadotropin production. Following reproductive
senescence, the gonads fail to produce significant quantities of
the gonadal sex hormones, abolishing the negative feedback
mechanisms keeping gonadotropin secretion in check.
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pathogenesis (67). Although plaques and neurofibrillary tan-
gles are the recognized neuropathological hallmarks of the
disease, evidence suggests that in the early stages of the dis-
ease, the “toxic principle” of AD may consist of A dimers or
small soluble oligomers of the peptide, that have been shown
in many in vitro studies to have neurotoxic and oxidative
stress-inducing properties (82).
APP PROCESSING 
AND OXIDATIVE STRESS
Many studies support the theory that the A peptide itself
is responsible, at least in part, for the AD-related oxidative
stress. It has been shown to be neurotoxic in many in vitro
models, most likely via the peptide’s ability to induce oxida-
tive damage (51). A can induce the overproduction of super-
oxide radicals by interaction with vascular endothelial cells
(121). The peptide can also induce the intracellular accumu-
lation of hydrogen peroxide in cultured neuroblastoma and
hippocampal neurons, and conversely antioxidants can atten-
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uate A-mediated neurotoxicity (17, 41, 42). In studies of
synaptosomes and cultured cortical cells, A has also been
found to induce oxidative damage including lipid peroxida-
tion (17). A also impairs mitochondrial function, potentially
increasing levels of free radicals generated via respiratory ox-
idative phosphorylation (1). Of relevance in the later stages
of AD, studies have found that amyloid plaques are a focus of
cellular and molecular oxidation (reviewed in Ref. 79).
The A peptide is a product of the proteolytic processing of
its much larger parent molecule APP (126). This transmembrane
APP molecule undergoes proteolytic processing by two compet-
ing pathways, the nonamyloidogenic and amyloidogenic path-
ways (Fig. 2). Sequential cleavage of APP by -secretase and -
secretase, respectively, thought to occur at the cell surface,
results in the secretion of soluble APP (-APPs) and nonamy-
loidogenic fragments. Alternatively, the cleavage of APP by
beta-site APP cleaving enzyme (BACE) and -secretase, thought
to occur following endocytosis of cell-surface APP, results in the
production of a different set of cleavage products including the
amyloidogenic A peptide (Fig. 2) (reviewed in Ref. 126).
It has been hypothesized that A accumulation increases
free radical generation beyond neural antioxidant capabili-
Non-Amyloidogenic
Pathway
Amyloidogenic
Pathway
N
APP
TM
C
E2/T LH
BACE
AICD
γ-secretase
FIG. 2. APP proteolytic processing pathways. Two competing pathways, the nonamyloidogenic and amyloidogenic pathways,
proteolytically cleave the majority of APP within the cell. In the nonamyloidogenic pathway, APP is cleaved with in the A domain
by -secretase to liberate a secreted form of APP (-APPs). A C-terminal fragment (C83/CTF) is left embedded in the membrane
for further cleavage into nonamyloidogenic fragments. In the amyloidogenic pathway, APP is first cleaved by BACE to liberate -
APPs. The C-terminal fragment (C99/-CTF) left embedded in the transmembrane (TM) is cleaved by the -secretase enzyme,
which consists of four proteins (PS1, Nicastrin, APH-1, and PEN-2) that interact with each other in a high molecular weight com-
plex. This cleavage event liberates the A40/A42 peptides. It is thought that another fragment is also released termed the APP in-
tracellular domain (AICD), that can translocate to the nucleus and activate gene transcription. Both pathways can be regulated by
reproductive hormones. Evidence suggests that high levels of estradiol (E2) or testosterone (T) drive APP processing towards the
nonamyloidogenic pathway and formation of the neuroprotective and neurotrophic -APPs metabolite. In contrast, high levels of
luteinizing hormone (LH) are thought to drive APP processing towards the amyloidogenic pathway and A formation. 
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ties, thus initiating oxidative stress-stimulated neurodegener-
ative cascades (24). The accumulation of A can also elicit
secondary neurodegenerative cascades such as inflammation,
thereby indirectly contributing more oxidative stress (96). In-
terestingly, oxidative stress may itself stimulate the formation
of the more toxic insoluble A aggregates, thereby exacerbat-
ing the neurotoxic activity of A and potentially leading to a
self perpetuating cycle of A accumulation and free radical
generation (65). Accordingly, it has been postulated that de-
creasing A production and/or improving its clearance may
lower oxidative stress and prevent the development of the
neurodegenerative cascades thought to lead to AD (128).
In contrast to studies of A, studies of secreted -APPs
have shown this protein to have antioxidant and neuroprotec-
tive properties, as it can attenuate free radical generation and
suppress A toxicity. In vitro studies have shown that the pro-
duction of -APPs stabilizes cellular calcium homeostasis
and protects neurons from metabolic, excitotoxic, and oxida-
tive insults (41, 80). This protective effect of -APPs extends
to in vivo studies, which have reported that the nonamyloido-
genic APP metabolite reduces damage to hippocampal neu-
rons following forebrain ischemia in rats (114).
REPRODUCTIVE HORMONES 
AND APP METABOLISM
The reproductive hormones, estrogen, testosterone, and
LH, all influence the metabolism of both the neurotoxic A
peptide and the neuroprotective APP fragment, -APPs. Es-
trogen has been reported to increase the secretion of -APPs
(56, 131), and to cause a decrease in A production in cul-
tured human neuroblastoma and cerebrocortical neurons (56).
In addition to promoting the nonamyloidogenic APP process-
ing pathway, estrogen has also been shown to inhibit APP
overexpression following ischemic injury (106), in turn re-
ducing substrate for APP processing and subsequent A pro-
duction. Apart from its effects on A production and accumu-
lation, estrogen also directly inhibits the neurotoxicity of the
peptide (16, 40, 47). In vivo, estrogen depletion (induced via
ovariectomy) results in significantly elevated A levels, par-
ticularly the more toxic A1–42 species, an effect that is par-
tially reversed following estrogen replacement (68, 95, 137).
Estrogen may also influence A accumulation via nonestro-
genic receptor-mediated mechanisms since the biologically
inactive 17-estradiol can similarly reduce A levels (68). It
is conceivable that estrogen reduces A accumulation in the
intact animal through modulation of both A production and
clearance. In support of this, estrogen has been found to stim-
ulate A clearance and degradation by microglial phagocyto-
sis (52, 69). Correspondingly, increased A burden and im-
paired microglial A clearance has been reported in an
estrogen-deficient transgenic mouse model of AD (133). In
this study, estrogen deficiency was induced by crossbreeding
transgenic mice overexpressing APP with aromatase knock-
out mice, aromatase being an enzyme responsible for con-
verting testosterone to estrogen. However, in direct contradic-
tion, another recent study has reported that estrogen depletion
induced by ovariectomy had no significant effect on A bur-
HORMONES IN ALZHEIMER’S DISEASE 2051
den in a transgenic mouse model of AD (45). This discrep-
ancy may result from differences in neural estrogen status,
since Yue et al. (133) found that ovariectomy was insufficient
to deplete estrogen levels in brain homogenate, whereas the
aromatase knockout mice exhibited significantly depleted
central and peripheral estrogen levels. It is interesting to note
that although ovariectomy is the commonly used experimen-
tal model of estrogen deficiency, it appears that at least in
some circumstances ovariectomy does not induce estrogen
depletion in the central nervous system. High estrogen activ-
ity has been demonstrated in the brain of ovariectomized
mice relative to other body regions using the estrogen-
responsive element-luciferase mouse model, which has been
engineered to express the nonmammalian luciferase protein
in response to classical estrogen receptor activation (27). This
confirms that central and peripheral estrogen homeostasis is
not necessarily synergistic, this is not a new concept, and this
observation was the first evidence for de novo synthesis of es-
trogen and other hormones in the brain (reviewed in Ref. 84).
Hence, peripheral estrogen status may not be an accurate in-
dication of central nervous system estrogen status. Depleted
estrogen levels have in fact been reported in brain ho-
mogenate of female AD patients (133).
Testosterone has also been implicated in the metabolism of
APP and A production (39, 44). In a manner similar to es-
trogen, testosterone treatment increases secretion of soluble
-APPs and simultaneously decreases A production (39). In
this study, the duration (but not the dose) of testosterone
treatment was found to correlate negatively with A produc-
tion (39). Since testosterone can be converted to estrogen by
aromatase in the brain, it is possible that estrogen synthesized
from the testosterone may be responsible for such effects on
APP metabolism. Aromatase inhibitors and dihydrotestos-
terone are being used to investigate whether testosterone has
a direct role in the modulation of A metabolism. Estrogen
and testosterone depletion induced via chemical castration in
men undergoing prostate cancer treatment is accompanied by
a significant increase in plasma A levels (4), and in men
with impaired memory function, free testosterone levels have
been found to correlate negatively with plasma A levels
(38). Interestingly, no correlation was found between A lev-
els and estradiol levels in this study, implying that testoster-
one is not influencing A metabolism entirely via its conver-
sion to estrogen. Nevertheless, human studies such as these
substantiate the purported roles of both estrogen and testos-
terone in the regulation of A burden.
Unlike estrogen and testosterone, LH has been implicated
in the promotion of amyloidogenic processing of APP (20).
LH treatment of cultured human neuroblastoma cells results
in dose-dependent increases in the accumulation of A and
amyloidogenic APP C-terminal fragments, whilst decreasing
secretion of soluble -APPs (20). Leuprolide treatment,
which inhibits both gonadotropin and estrogen production,
has been used to study the effect of LH suppression on A
production in female mice (20, 25). LH suppression was
found to decrease brain A levels, particularly the longer,
more toxic A1–42 species (20, 25). This result was surpris-
ing since estrogen depletion is known to be associated with
elevated A levels, yet despite estrogen depletion induced by
chemical gonadoectomy, A levels were reduced. Casadesus
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et al. (25) argued that this demonstrates LH has a much
greater capacity to modulate A levels than the sex hor-
mones. If so, the gonadectomy model of reproductive senes-
cence should be reconsidered since LH and sex hormone ho-
meostasis are intrinsically linked. Ideally, new models need to
be developed to discern the individual contributions of LH
and each of the gonadal sex hormones in neurodegenerative
processes.
Since A has been identified as a key protein in AD patho-
genesis, potentially even playing a role in the initiation of the
neurodegenerative process, considerable drug development
has focused upon modifying the production and metabolism
of this protein (92). Given the antiamyloidogenic properties
of estrogen and testosterone, HRT may help minimize A
burden and consequently reduce oxidative injury. However, in
light of the recent evidence indicating that LH potently facili-
tates A production, irrespective of gonadal sex hormone sta-
tus, gonadotropin-suppressing agents such as leuprolide may
have greater antiamyloidogenic potential than the gonadal sex
hormones (reviewed in Ref. 14). Accordingly, leuprolide has
recently been shown to attenuate cognitive decline and A
deposition in AD transgenic mice and is currently undergoing
clinical trials for the treatment of AD (25).
ANTIOXIDANT PROPERTIES OF THE
GONADAL STEROID HORMONES
Estrogens have been coined ‘natural antioxidants’ since
they have been demonstrated to inhibit lipid peroxidation in a
variety of biological systems. In microsomal lipid prepara-
tions, estrogens have been reported to inhibit iron-induced
lipid peroxidation (116). Similar antioxidant properties of es-
trogens have been reported in tissues of the central nervous
system. In vitro, 17-estradiol is a more potent inhibitor of
oxidative stress than -tocopherol in a range of neuronal cell
models, protecting against oxidative damage and cell death
mediated by the reactive oxygen species, hydrogen peroxide
(15, 16). 17-Estradiol and estriol have also been demon-
strated to increase neuronal survival and reduce lipid peroxi-
dation in response to iron-induced oxidative stress (40), and
to decrease mitochondrial production of reactive oxygen
species in a dose-dependent manner (28). Furthermore, 17-
estradiol inhibits iron induced lipid peroxidation in both rat
and human brain homogenates (124).
Although some of the neuroprotective effects of estrogen
that have been documented are the result of classical estro-
gen-receptor mediated signaling pathways, the antioxidant
properties of estrogens are mediated by receptor-independent
mechanisms (15). The concentrations of estrogens necessary
to elicit these antioxidant effects in both the central nervous
system and peripheral biological systems far exceed normal
physiological concentrations, indicating that these neuropro-
tective properties are not mediated by the estrogen receptor
(15). Supporting this notion, the antioxidant effects of the es-
trogens have been confirmed in neuronal cell lines that do not
express estrogen receptors (16). Furthermore, the antioxidant
properties of estrogens cannot be significantly attenuated by
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co-administration of a competitive estrogen receptor antago-
nist, or a protein synthesis inhibitor (28, 102, 115). Biologi-
cally inactive estrogen forms (with respect to the estrogen re-
ceptor) such as 17-estradiol also exhibit antioxidant activity,
again indicating receptor-independent antioxidant activity
(15, 102). Comparisons of the antioxidant capacities of estro-
gens in neuronal cell culture have led to the identification of
the hydroxyl group located at position 3 of the phenoxyl ring
of estrogen as an important structural feature for estrogenic
antioxidant activity (15, 101). The phenolic structure of estro-
gens enables the direct scavenging of free radicals by the do-
nation of hydrogen to lipid peroxyradicals, thus terminating
oxidative chain reactions (115, 116).
In direct contrast to the free radical scavenging capacity of
estrogens, some studies have implicated high concentrations
of estrogens in metabolic reactions that generate free radicals
(70). Estradiol can be enzymatically metabolized into cate-
chol estrogens, which have an additional hydroxyl- or
methoxy- group substituted in the ortho- position of the phe-
nolic hydroxyl group of the estrogen (70). The hydroxyl- (but
not methylated-) substituted catechol estrogens are readily
oxidized, and undergo redox cycling to produce free radicals
(70). Elevated levels of estrogens result in increased catechol
estrogen redox cycling, thus promoting the formation of the
reactive oxygen species (70). These processes have been of
interest in cancer research, due to the potential oxidative
damage resulting from elevated estrogen levels in tissues that
readily catalyze catechol estrogen formation (70, 71). The
physiological significance of these metabolic pathways in the
brain is not well understood; however, catechol estrogens
have been detected throughout the brain (93) and limited ox-
idative metabolism of catechol estrogens has been demon-
strated in brain microsomes (58). Whilst the antioxidant
properties of supra-physiological estrogen levels are well
documented, we can only speculate about the potential pro-
oxidant properties of estrogen in the brain. The potential
long-term effects of supra-physiological estrogen concentra-
tions must be determined prior to considering the clinical use
of estrogens as an antioxidant.
The potential antioxidant effects of the other steroidal hor-
mones, progesterone and testosterone, have also been ex-
plored. Progesterone was found to be far less effective at in-
hibiting lipid peroxidation and neural death than either
estradiol or estriol (40). However, slight antioxidant properties
of progesterone occur in response to iron-induced oxidative
stress in neural cells, whilst testosterone offers no neuropro-
tective benefit (40). Similarly, progesterone but not testoster-
one reduces iron-induced lipid peroxidation significantly in
cultured hippocampal cell homogenates; however, neither pro-
gesterone nor testosterone elicited any effect on iron-induced
lipid peroxidation in human brain homogenates (124). Proges-
terone does not improve neuronal survival following hydrogen
peroxide treatment (16), yet testosterone exhibits neuroprotec-
tive effects in cerebellar granule cells against oxidative insults
mediated by the reactive oxygen species, hydrogen peroxide
and nitric oxide (NO) (2, 3). These neuroprotective effects
were suggested to be mediated by estrogen, following the con-
version of testosterone to estrogen by aromatase (7). However,
the antioxidant properties of testosterone can be attenuated by
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flutamide, an androgen receptor antagonist (2). Furthermore,
unlike testosterone, estrogen does not yield any neuroprotec-
tive effect in the cerebellar granule cell oxidative stress model
(3). Testosterone is now thought to mediate its antioxidant ef-
fects by upregulation of the antioxidant enzymes superoxide
dismutase and catalase through the androgen receptor, rather
than via conversion to estrogen or via direct scavenging activ-
ity (2, 3). This is supported by evidence that testosterone treat-
ment results in significant elevations of the superoxide dismu-
tase and catalase enzymes in the cerebellum (2, 3).
Testosterone has also been implicated in the regulation of glu-
tathione, with increased levels reported in rat brain ho-
mogenate following testosterone treatment (6). Whilst the
neuroprotective effect of testosterone is well established, fur-
ther assessment of the underlying mechanisms is necessary, to
determine the degree to which neuroprotection is afforded by
its antioxidant properties.
In addition to acting as a free radical scavenger, estrogen
has also been implicated in the regulation of endogenous an-
tioxidants and enzymes associated with their metabolism
(103, 104). Estrogen dose-dependently increases glutathione
levels in glial, hippocampal, and cortical neuron cultures
(104). Catalase activity is differentially affected by estrogen
in glial and hippocampal cultures, estrogen treatment in-
creases catalase activity in glial cells, yet decreases catalase
activity in hippocampal cells (103). In vivo, ovariectomy has
been associated with increased catalase levels yet unchanged
glutathione and superoxide dismutase levels (86, 90). Post-
menopausal women also have altered levels of antioxidant en-
zymes compared to women of reproductive age (77, 129) and
glutathione peroxidase levels correlate positively with serum
estradiol levels in women on HRT (77). Premenopausal
women have also been reported to possess significantly
higher glutathione peroxidase levels than males of the same
age (77). As previously discussed, evidence indicates that
compensatory mechanisms have already resulted in signifi-
cantly elevated glutathione levels in AD brains. It is not
known if HRT would increase glutathione levels even further
in AD patients, and if so, whether this would elicit any clini-
cal benefit in the treatment of AD.
Clinical research has linked antioxidant therapy to the
prevention and delay of AD (reviewed in Ref. 23). The clini-
cal use of estrogens as antioxidants may be limited due to
their hormonal actions, including their oncogenic effects on
reproductive tissues, and their feminizing effects in men.
Furthermore, the high doses of estrogen necessary to elicit
antioxidant activity have the potential to increase free radi-
cal production through catechol estrogen metabolism when
administered long-term. Synthetic estrogens with greater
scavenging activity have already been developed for use in
cancer treatments, to eliminate potential problems arising
from increased estrogenic action through classical signaling
pathways (46). Selective estrogen receptor modulators
(SERMS) have been developed for the treatment of hor-
monal driven cancer to antagonize estrogenic effects on re-
productive organs, whilst preserving the beneficial actions
of estrogen on other organs (120). These compounds may
prove clinically useful in antioxidant therapy for the preven-
tion and delay of AD.
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NEUROINFLAMMATION AND
REPRODUCTIVE HORMONES
Chronic inflammation has been identified as an important
neurodegenerative process contributing to AD. For example,
inflammatory molecules including cytokines are upregulated
in AD brains, and activated astrocytes and microglia are ob-
served within and in close proximity to senile plaques (81).
Inflammatory molecules secreted by activated astrocytes and
microglia are potentially toxic and provide yet another source
of oxidative stress. Microglial activation provokes respiratory
burst activity, resulting in the production of the superoxide
anion, which can then subsequently be converted to other re-
active oxygen species such as hydrogen peroxide, or the very
potent hydroxyl radical (10). Activated microglia also secrete
the reactive nitrogen species, NO, which is synthesized by in-
ducible nitric oxide synthase (iNOS). Similarly, astrocytes
have been implicated in the production of NO, in addition to
playing a pivotal role in mediating microglial activation (10).
Activation of inflammatory processes in AD may be the result
of A deposition (96), a notion supported by evidence that
microglia may play a role in the phagocytosis and degrada-
tion of this peptide (35). Conversely, there is also evidence
that A deposition is the result of inflammation since acti-
vated microglia upregulate APP expression resulting in in-
creased production of A (11). Whilst these inflammatory
processes may lead to oxidative stress, oxidative stress also
triggers inflammatory responses including astrocytic and mi-
croglial activation, potentially amplifying neurodegenerative
cascades.
It is interesting to note that inflammation can influence re-
productive hormone homeostasis, and likewise, the reproduc-
tive hormones can influence the regulation of inflammatory
reactions (34). For example, altered immune responses have
been noted during menopause, and it has been found that
HRT can reverse these changes (64). Furthermore, immune
suppression during pregnancy is believed to be mediated by
the reproductive hormones (72). The monthly cyclic hormone
changes in women are also associated with changes in in-
flammatory markers, including elevated free radical produc-
tion immediately prior to ovulation (107). The role of estro-
gen in vascular inflammation has received a lot of attention
because of the potential implications for the modulation of
cardiovascular disease risk. Similarly, the reproductive hor-
mones have been implicated in the modulation of inflamma-
tory responses in the central nervous system. Evidence indi-
cates that the sex hormones and LH have opposite effects on
inflammatory processes—a relationship between these hor-
mones that is now being reported regularly. Estrogen and tes-
tosterone have an anti-inflammatory activity, inhibiting the
activation of microglia and astrocytes, whilst LH is impli-
cated in pro-inflammatory signaling pathways.
Neurosteroids and gonadal sex hormones modulate in-
flammatory responses of astroglia following neural injury.
The gonadal hormones, 17-estradiol, progesterone, and
testosterone, have all been shown to decrease reactive glio-
sis in ovariectomized or castrated rats following penetrating
brain injury (36). Similarly, 17-estradiol, progesterone,
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dehydroepiandrosterone (DHEA), and pregnenolone have
all been found to decrease reactive gliosis in castrated male
rats in response to penetrating brain injury, indicating the
hormone treatment inhibited astrocyte proliferation and/or
migration (36). In this study the neuroactive steroid, DHEA,
was found to be the most potent inhibitor of reactive gliosis
(36). There is also evidence that brain injury upregulates de
novo synthesis of estrogen from testosterone in astrocytes
(37), indicating that in this model at least some of the ef-
fects of testosterone may be due to its conversion to estro-
gen. Neurosteroids and gonadal sex hormones also have the
capacity to induce morphological changes in astrocytes
(30). 17-Estradiol, testosterone, and pregnenolone, but not
progesterone, have been found to increase the number of
GFAP-immunoreactive astrocyte processes, perhaps indica-
tive of astrocyte arborization (30). It is clear that estrogen
not only has the capacity to suppress reactive gliosis follow-
ing injury, but can also modulate potential neuroprotective
activities of astrocytes.
Estrogen has also been implicated in the regulation of a
wide range of microglial functions, including expression of
cytokines, cell surface molecules, apoptotic signaling path-
ways, and free radical generation (31). Cultured microglial
cells exhibit respiratory burst activity, phagocytic activity,
iNOS expression, and subsequent NO production in re-
sponse to inflammatory stimuli, all of which can be inhib-
ited by estrogen in a dose-dependent manner (127, 129).
These studies suggest that in vivo production of reactive
oxygen and nitrogen species by activated microglia could be
inhibited by estrogen treatment, thereby reducing the oxida-
tive burden caused by chronic inflammatory responses.
Similarly, estrogen has been implicated in the modulation of
NO production from peripheral macrophages (53). Pre-
incubation of microglial cultures with DHEA also decreases
NO secretion, but not iNOS expression (12). The inhibitory
effects of estrogen on microglial activation are dependent
upon the estrogen receptor, since the biologically inactive
17-estradiol has no effect on microglial responses (21) and
estrogen receptor antagonists abolish the inhibitory effects
of estrogen (125). It has been hypothesized that the estrogen
receptor acts through the mitogen activated protein kinases
(MAPKs) to moderate microglial responses, since MAPK
inhibitors also attenuate the effects of estrogen on mi-
croglial activation (21). Interestingly, estrogen was found to
attenuate microglial activation only when estrogen treat-
ment was given to the cultures prior to inflammatory insult,
indicating estrogen does not have the capacity to modulate
inflammatory reactions once microglial activation has been
initiated (125).
The LH receptor has been found to be expressed on a di-
verse range of immune cells throughout the body, suggesting
that the immune system is a target for the gonadotropin hor-
mones. Immune cells that express LH receptors include blood
leukocytes (72, 135), follicular and endometrial macrophages
(136), and macrophages of the human brain (22). A disparate
range of effects of the gonadotropin hormones on immune re-
sponses in the periphery has been described. Much research
has focused upon the role of human chorionic gonadotropin
(hCG) in inflammatory responses due to its role in immuno-
suppression during pregnancy. The effects of hCG on periph-
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eral inflammatory processes may provide insight into poten-
tial effects of LH, as both hormones mediate their biological
actions through a common receptor, the LH receptor. HCG
has been reported to dose dependently and reversibly inhibit
lymphocyte proliferation in response to inflammatory stimuli
(49). Furthermore, in vitro investigations have found that
high concentrations of hCG stimulate the production of the
anti-inflammatory cytokines interleukin-8 and interleukin-2
from blood leukocytes (63). In contrast to hCG, however, LH
has been implicated in pro-inflammatory and pro-oxidant
generation, which is believed to play an important role in lu-
teolysis and ovulation. For example, LH dose-dependently in-
creases secretion of reactive oxygen and nitrogen species
from human blood leukocytes (107). Gonadotropin-mediated
increased production of reactive nitrogen species may be the
result of iNOS upregulation, since hCG has been demon-
strated to upregulate iNOS expression in macrophages (62).
It is evident that in the periphery the gonadotropins have
pluripotent effects on inflammation, differentially potentiat-
ing or suppressing inflammation depending on conditions
and tissue type.
Whilst researchers have suggested LH has a potential role
in the regulation of inflammatory reactions in the brain (13),
there has been limited investigation. Although LH receptors
have been detected on brain macrophages, no studies have in-
vestigated the effect of LH on these cells. In immortalized
hippocampal cultures, binding to the LH receptors mediates
the upregulation of 5-lipoxygenase, an enzyme important in
pro-inflammatory signaling pathways (134). Lipoxygenases
are lipid peroxidizing enzymes that metabolize arachidonic
acid, generating free radicals and inflammatory leukotrienes.
Further investigation is required to confirm if LH receptor-
dependent upregulation of 5-lipoxygenase induces the clas-
sical lipoxygenase signaling pathways, leading to the produc-
tion of pro-inflammatory and pro-oxidant species. LH has
been found to activate similar signaling pathways in gonadal
tissue, where LH receptor-dependent cAMP/protein kinase A
phosphorylation subsequently activates the lipoxygenase/
arachidonic acid signaling pathway (83, 119). 5-Lipoxyge-
nase is expressed at particularly high levels in the hippocam-
pus and the cerebellum (66), and age-related dysregulation of
5-lipoxygenase transcription results in increased 5-lipoxy-
genase expression in aged animals (99, 123). Therefore, it
may be conceivable that elevated LH levels that occur follow-
ing reproductive senescence may increase 5-lipoxygenase
signaling in the LH receptor-rich hippocampus, stimulating
inflammation and oxidative stress. In light of the age-related
increase in 5-lipoxygenase expression, lipoxygenase inhibitors
have been recognized as potentially useful in the treatment of
AD (74).
The risks associated with long-term HRT diminish the po-
tential for the use of estrogen as an anti-inflammatory agent
in the treatment of AD. Since estrogen mediates its anti-
inflammatory activity via the estrogen receptor, the synthetic
estrogens–selective estrogen receptor modulators–will not
mimic the anti-inflammatory properties of estrogen. Further-
more, given that estrogen cannot alter microglial activation
once an inflammatory response has been initiated, the anti-
inflammatory benefits of estrogen may be limited to preven-
tion rather than treatment.
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CONCLUSIONS
A diverse and complex network of inextricably linked
neurodegenerative processes contribute to the generation of
oxidative stress in AD. It is likely that multiple factors com-
bine to create a neural environment that facilitates oxidative
injury; although in some instances a single initiating factor
may be sufficient to trigger the neurodegenerative cascade.
According to the popular AD hypothesis, the “amyloid hy-
pothesis,” oxidative stress and inflammation are closely
linked but secondary to the primary cause, which is the accu-
mulation of A. However, oxidative stress induced by other
factors can also contribute to inflammation and amyloidogen-
esis, initiating a vicious cycle.
Dysregulation of the reproductive hormones, estrogen, pro-
gesterone, testosterone, and LH, has been associated with AD
etiology and pathology. Regulation of these hormones is
tightly linked, and following reproductive senescence go-
nadal sex hormone depletion is coupled to elevated LH lev-
els. Given the neuroprotective mechanisms of gonadal sex
hormones described here, including antioxidant, anti-inflam-
matory, and anti-amyloidogenic properties, it seems surpris-
ing that the recent Women’s Health Initiative clinical trial has
found HRT to be detrimental to cognitive health in women
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(32, 109). If the clinical neuroprotective benefit of HRT is to
be definitively clarified, dosage and duration of treatment
will need to be offset against risks of potential negative ef-
fects associated with long-term HRT, including increased risk
of breast cancer, pulmonary embolism, and stroke. Further,
since estrogen has been identified as a potential proconvul-
sive, the cost–benefit of estrogen use should be individually
assessed in patients with seizure disorders (reviewed in Ref.
33). Whilst the potential benefits of HRT may be revisited to
resolve issues associated with the age at initiation of HRT, the
amyloidogenic and potentially inflammatory properties of
LH may also in part help explain the inconsistencies in the ef-
fects of HRT on AD risk. It is conceivable that the combined
effects of the sex steroids and gonadotropins may influence
the susceptibility to and progression of neurodegeneration.
The research reviewed here indicates that elevated sex hor-
mone levels combined with low cycling LH levels during the
reproductive years may promote antioxidant activity, sup-
press inflammation, and reduce A accumulation (Fig. 3).
Following reproductive senescence, the depleted sex hor-
mones combined with elevated LH levels promote A pro-
duction and inflammation, and potentially exacerbate oxida-
tive stress (Fig. 4). Given the diverse actions of the
reproductive hormones, combinational hormone therapy may
prove to be more efficacious in the prevention of AD, though
this notion needs to be tested in further studies.
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ABBREVIATIONS
-APPs, secreted protein produced by cleavage of trans-
membrane APP with APP -secretase enzyme; A, amyloid
peptide produced by proteolytic cleavage of APP by BACE
and -secretase; AD, Alzheimer’s disease; APP, amyloid pre-
cursor protein; BACE, -site APP cleaving enzyme; DHEA,
dihydroepiandrosterone; GnRH, gonadotropin releasing hor-
mone; HRT, hormone replacement therapy; GFAP, glial fib-
rillary acidic protein; hCG, human chorionic gonadotropin;
iNOS, inducible nitric oxide synthase; LH, luteinizing hor-
mone; MAPK, mitogen activated protein kinase; MPA,
medroxyprogesterone acetate; NO, nitric oxide; SERMS, se-
lective estrogen receptor modulators; WHI, Women’s Health
Initiative.
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FIG. 3. Hormonal interactions with oxidative stress path-
ways whilst reproductively functional. High estrogen (E2)
and progesterone (P) in women and testosterone (T) in men
promotes A clearance by microglial phagoctytosis and de-
creases A production, thereby reducing oxidative burden of-
fered by the A peptide. Reduced A production is coupled
with increased -APPs production, which contributes neuro-
protective and antioxidant properties. Estrogen can also act di-
rectly as an antioxidant; however, normal physiological con-
centrations are likely to be too low to offer any benefit.
Estrogen and testosterone may also suppress potentially neu-
rodegenerative chronic inflammatory processes, preventing
overproduction of free radicals and other neurotoxic inflamma-
tory products.
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